Allied Academies welcomes you to attend “Global Congress on Cancer Science and Therapy” held in the beautiful city of Madrid, Spain on August 23 - 24 with the theme “Understanding cancer and treatment for a better world”. We amiably invite you to attend the conference and share your research on Cancer Science and Therapy. Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament.
- Chiefs/Managers and Business Delegates
- Director of Laboratories
- Post-Doctoral Fellows
- Research and Diagnostic Laboratories
- Clinical Fellows
- Research Scholars
- Technology Experts
- Biomedical Research organizations
- Medical oncologists
- Surgical oncologists
Allied Academies cordially welcomes all the participants and contributors from worldwide to attend the Conference .It is to spread knowledge, awareness,and education about the recent advances in the treatment of cancer and development of a new treatment to reduce the death rate because of cancer and to develop painless treatment of cancer. With people from around the world focused on getting some answers concerning Cancer Science and Therapy,this is your single most obvious opportunity to accomplish the greatest accumulation of individuals from the mending focuses, Universities, bunch,etc.
Despite remarkable progress in the discovery and
development of novel cancer therapeutics, cancer
remains the second leading cause of death in the world. For many years,
compounds derived from plants have been at the forefront as an important source
of anticancer therapies and
have played a vital role in the prevention and treatment of cancer because of their
availability, and relatively low toxicity when compared with chemotherapy. More
than 3000 plant species have been reported to treat cancer and
about thirty plant-derived compounds have been isolated so far and have been
tested in cancer clinical trials.
The mechanisms of action of plant-derived anticancer drugs are numerous and
most of them induce apoptotic cell death that may be intrinsic or extrinsic,
and caspase and/or p53-dependent or independent mechanisms. Alternative modes
of cell death by plant-derived anticancer drugs are emerging and include mainly
autophagy, necrosis-like programmed cell death, mitotic catastrophe, and
senescence leading to cell death. Considering that the non-apoptotic cell death
mechanisms of plant-derived anticancer drugs are less reviewed than the
apoptotic ones, this paper attempts to focus on such alternative cell death
pathways for some representative anticancer plant natural compounds in clinical
development. In particular, emphasis will be on some promising polyphenolics
such as resveratrol, curcumin, and genistein; alkaloids namely berberine,
noscapine, and colchicine; terpenoids such as parthenolide, triptolide, and
betulinic acid; and the organosulfur compound sulforaphane. The understanding
of non-apoptotic cell death mechanisms induced by these drugs would provide
insights into the possibility of exploiting novel molecular pathways and
targets of plant-derived compounds for future cancer therapeutics.
- Mechanisms and regulation of classical apoptotic
and non-classical modes of cell death.
- Mechanistic insight into autophagy and senescence
- Therapeutic strategies
modulating cell death in cancer cells
Session 2: Basic Science to Clinical Trials
The effective management of malignant melanoma has remained centred around the surgeon. The arrival of anti-angiogenic agents as the ‘fourth’ cancer treatment joining the ranks of surgery, chemotherapy and radiotherapy has been a source of renewed hope. This provides an up-to-date review of the focus, state and rationale of clinical trials of anti-angiogenic therapies in metastatic malignant melanoma. Vascular Endothelial Growth Factor (VEGF) is by no means the only target, although perhaps the most extensively studied following the successful introduction of the anti-VEGF Antibody bevacizumab. This has been combined with other established therapies to try and improve outcomes in metastatic disease, and is being trialled in the UK to prevent metastasis in high-risk patients. We describe the encouraging preclinical work that lead to great enthusiasm for these agents, assess the key trials and their outcomes.
· Embryonic stem cells
· Therapeutic target in cancer
· Drug development
Session 3: Molecular Pathology Approach to Cancer
Molecular pathology is one of the linchpins of precision medicine. No longer can treatment decisions related to therapy selection be rendered solely on the basis of histopathological analyses, as genomic analyses of human cancers are resulting in the identification of the genetic determinants of tumourigenesis, cancer progression and therapy response.
Session 4: Mechanisms to therapies
Several scientific and clinical studies have shown an association between chronic alcohol consumption and the occurrence of cancer in humans. The mechanism for alcohol-induced carcinogenesis has not been fully understood, although possible events include genotoxic effects of acetaldehyde, cytochrome P450 2E1 (CYP2E1)-mediated generation of reactive oxygen species, aberrant metabolism of folate and retinoids, increased estrogen, and genetic polymorphisms. The impact of alcohol drinking on the risk of cancer development and potential underlying molecular mechanisms. The interactions between alcohol abuse, anti-tumor immune response, tumor growth, and metastasis are complex. However, multiple studies have linked the immunosuppressive effects of alcohol with tumor progression and metastasis. The influence of alcohol on the host immune system and the development of possible effective immunotherapy for cancer in alcoholics are also discussed. The conclusive biological effects of alcohol on tumor progression and malignancy have not been investigated extensively using an animal model that mimics the human disease. The review provides insights into cancer pathogenesis in alcoholics, alcohol and immune interactions in different cancers, and scope and future of targeted immunotherapeutic modalities in patients with alcohol abuse.
Session 5: Cancer Precision Medicine
Through the precision medicine approach, the treatment of each patient can be focused on drugs most likely to benefit him or her, sparing the patient the cost and potential harmful side effects from drugs that are unlikely to be beneficial. For example, drugs targeted to the HER2 protein are offered only to the 20 percent of breast cancer patients who have disease that tests positive for high levels of HER2.
- Trials in Low survival rate cancers
- Cellular stress
- Emerging techniques in biomarker discovery drug development and patient stratification
Session 6: Immunotherapy of Cancer
Immunotherapy, also called biologic therapy, is a type of cancer treatment that boosts the body's natural defenses to fight the cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function. Immunotherapy may work in these ways.
- Stopping or slowing the growth of cancer cells
- Stopping cancer from spreading to other parts of the body
- Helping the immune system work better at destroying cancer cells
There are several types of immunotherapy, including:
- Monoclonal antibodies
- Non-specific immunotherapies
- Oncolytic virus therapy
- T-cell therapy
- Cancer vaccines
Session7: Signalling Pathways in Cancer
Cancer is driven by genetic and epigenetic alterations that allow cells to over proliferate and escape mechanisms that normally control their survival and migration. Many of these alterations map to signaling pathways that control cell growth and division, cell death, cell fate, and cell motility, and can be placed in the context of distortions of wider signaling networks that fuel cancer progression, such as changes in the tumor microenvironment, angiogenesis, and inflammation. Mutations that convert cellular proto-oncogenes to oncogenes can cause hyper activation of these signaling pathways, whereas inactivation of tumor suppressors eliminates critical negative regulators of signaling. An examination of the PI3K-Akt and Ras-ERK pathways illustrates how such alterations dysregulate signaling in cancer and produces many of the characteristic features of tumor cells.
Session 8: Modes of Cancer Spread
Metastasis is a pathogenic agent's spread from an initial or primary site to a different or secondary site within the host's body; it is typically spoken of as such spread by a cancerous tumor. The newly pathological sites, then, are metastases (mets). Cancer occurs after cells are genetically altered to proliferate rapidly and indefinitely. This uncontrolled proliferation by mitosis produces a primary heterogeneic tumour. The cells which constitute the tumor eventually undergo metaplasia, followed by anaplasia then dysplasia, resulting in a malignant phenotype. This malignancy allows for invasion into the circulation, followed by invasion to a second site for tumorigenesis.
Session 9: Familial Cancer
Cancer that occurs in families more often than
would be expected by chance. These cancers often
occur at an early age, and may indicate the presence of a gene mutation
that increases the risk of cancer.
They may also be a sign of shared environmental or lifestyle factors.
Session 10: Economic Impact on Cancer
Distribution in economics refers to the way total output, income, or wealth is distributed among individuals or among the factors of production (such as labour, land, and capital). In general theory and the national income and product accounts, each unit of output corresponds to a unit of income. Cancer can be a major cause of lack of money. This may be due either to the costs of treating and managing the illness as well as its impact upon people's ability to work. This particularly affects countries that lack comprehensive social health insurance systems and other types of social safety nets. The study is a longitudinal short study of 10,000 hospital patients with a first time diagnosis of cancer. Patients were assigned a socioeconomic status according to the district of residence at diagnosis. Continuity of patients due to cancer living in the most deprived district was compared to survival of patients living in all other districts by model-based period analysis. These major regional socioeconomic inequalities indicate a potential for improving cancer care and survival in Germany. Studies on individual patient data with access to cancer treatment information should be conducted to examine the reasons for these socioeconomic inequalities in cancer survival.
Session 11: Cancer and Alternative Medicine
Ayush system is the most common term used for the cancer treatment. Ayurvedic medicine is an ancient Indian system of medicine which began about 5,000 years ago. It is not just one treatment. It is a way of diagnosing illness and using a wide range of treatments and techniques. Herbal medicine uses plants, or mixtures of plant extracts, to treat illness and promote health. It aims to restore your body's ability to protect, regulate and heal itself. It is a whole body approach, so looks at your physical, mental and emotional wellbeing. It is sometimes called phytomedicine, phytotherapy or botanical medicine. Naturopathic doctors (NDs) believe that cancer arises from an imbalance that causes a systemic breakdown within the body. Homeopathy is based on the theory of treating like with like. So to treat an illness a homeopathic therapist (homeopath) uses tiny doses of a substance that in large doses would actually cause the symptoms of the illness.
Session 12: Cancer Biomarkers
Protein Biomarkers can be used as biomarkers for early detection of cancers especially used for the identification of breast cancer. Diagnostic Patients with suspected pancreatic cancer will undergo an initial CT scan to determine if a suspect mass is localized and removed by surgery 63% of patients will be diagnosed with non-resectable stage III and IV disease and a biopsy will be undertaken to confirm pancreatic cancer by H&E pathological analysis. The presence of cancerous cells via pathology is very challenging due to high numbers of non-cancerous stromal infiltrating cells and administration of chemotherapy or enrolment into a clinical trial will only commence on definitive diagnosis of pancreatic cancer. These will notice specifically stains neoplastic pancreatic cells would enable the pathologist to confidently diagnose pancreatic cancer and thus offer appropriate cancer treatment to the patients. The Novel Biomarker BI-010 has been identified as a highly sensitive (98%) and specific (95%) IHC marker for pancreatic cancer and CRT is seeking a partner to develop an IHC based test to detect BI-010 in fine needle aspirate biopsies from biopsy samples.
Session 13: Diagnostics and Staging
X-radiation (composed of X-rays) is a form of electromagnetic radiation Magnetic resonance imaging (MRI) is a type of scan that uses strong magnetic fields and radio waves to produce detailed images of the inside of the body. An ultrasound scan, sometimes called a sonogram, is a procedure that uses high-frequency sound waves to create an image of part of the inside of the body. A biopsy is a medical test commonly performed by a surgeon, interventional radiologist, or an interventional cardiologist involving sampling of cells or tissues for examination. A complete blood count (CBC) gives important information about the kinds and numbers of cells in the blood, especially red blood cells, white blood cells, and platelets. Cancer staging is the process of determining the extent to which a cancer has developed by spreading. The TNM Classification of Malignant Tumours (TNM) is a cancer staging notation system that gives codes to describe the stage of a person's cancer, when this originates with a solid tumour. Pathologic staging, where a pathologist examines sections of tissue, can be particularly problematic for two specific reasons: visual discretion and random sampling of tissue.
Session 14: Radiation oncology
Radiation oncology is one of the three primary specialties, the other two being surgical and medical oncology, involved in the treatment of cancer. A Radiation Oncologist is a specialist physician who uses ionizing radiation (such as megavoltage X-rays or radionuclides) in the treatment of cancer. Brachytherapy is an advanced cancer treatment. Radioactive seeds or sources are placed in or near the tumour itself, giving a high radiation dose to the tumour while reducing the radiation exposure in the surrounding healthy tissues. External beam therapy (EBT), also called external radiation therapy, is a method for delivering a beam or several beams of high-energy x-rays to a patient's tumour. Intraoperative radiation therapy or IORT is the application of therapeutic levels of radiation to the tumour bed while the area is exposed during surgery. Systemic radiation therapy is a type of radiation therapy in which radioactive material travels through the bloodstream to reach cells all over the body. Systemic radiation is used to treat certain types of cancer, such as thyroid cancer, or to relieve pain when cancer has spread (metastasized) to the bone. Radio immunotherapy (RIT) uses an antibody labelled with a radionuclide to deliver cytotoxic radiation to a target cell. In cancer therapy, an antibody with specificity for a tumour-associated antigen is used to deliver a lethal dose of radiation to the tumour cells to relieve pain when cancer has spread (metastasized) to the bone. Radio immunotherapy (RIT) uses an antibody labelled with a radionuclide to deliver cytotoxic radiation to a target cell. In cancer therapy, an antibody with specificity for a tumour-associated antigen is used to deliver a lethal dose of radiation to the tumour cells.
Session 15: Chemotherapy
Chemotherapeutic agent an agent used to treat cancer administered in regimens of one or more cycles, combining two or more agents over a period of days to weeks. Intravenous chemotherapy is one way to receive cancer-fighting medicine. Oral chemotherapy (chemo) is a treatment used to shrink a tumour or kill cancer cells. Oral chemo is usually taken in the form of a pill or capsule. Arterial chemotherapy infusion of the liver and chemoembolization of the liver (transarterial chemoembolization or TACE) are similar procedures that are used for the treatment of cancers in the liver. Adjuvant therapy or care, also called adjunct therapy or adjunctive therapy or care, is therapy that is given in addition to the primary, main, or initial therapy to maximize its effectiveness. Topical chemotherapy is a cream or lotion applied directly to the skin cancer. Different drugs cause different side effects. Certain types of chemotherapy often have specific side effects. But, each person’s experience is different.
The global cancer
diagnostics market was valued at USD 101.0 billion in 2013 and is expected to
grow at a CAGR of 7.6% from 2014 to 2020, to reach an estimated value of USD
168.6 billion in 2020. The global cancer biomarkers market is expected to reach
USD 15,973.8 Million by 2020, at a CAGR of 11.6% from 2015 to 2020. In 2010,
the global cancer market was valued at $54 billion, with
forecasted Compound Annual Growth Rate (CAGR) growth to $81 billion by 2016.
The seven major cancer markets (US, France, Germany, Italy,
Spain, United Kingdom and Japan) represented ~79% of the 2010 global cancer market ($43 billion). The US dominated
2010 sales with a market share of 38.5% and the leading ten companies of the
market represented 87.1%
($47 billion) of the total market.
Spain, a country on Europe’s Iberian Peninsula, includes 17 autonomous regions with diverse geography and cultures. Capital city Madrid is home to the Royal Palace and Prado museum, housing works by European masters. Segovia has a medieval castle and an intact Roman aqueduct. Catalonia’s capital, Barcelona, is defined by Antoni Gaudí’s whimsical modernist landmarks like the Sagrada Família church.
Societies and Universities Associated with oncology and cancer research:
Society of Oncology and Cancer Research of Nigeria (SOCRON)
European society for medical oncology
American Society of Clinical Oncology
Swiss Group for Clinical Cancer Research
American Institute for Cancer Research (AICR)
National Foundation for Cancer Research
Cancer Research Institute
Institute of Cancer Research, London
European Academy of Tumor Immunology (EATI)
American Association for Cancer Research (AACR)
National Cancer Institute
Cancer Research UK
Memorial Sloan Kettering Cancer Center
Ludwig Institute for Cancer Research
National Institutes of Health (NIH)
Breast Cancer Research Foundation
University of Texas MD Anderson Cancer Center
World Cancer Research Fund International
Dana–Farber Cancer Institute
Prevent Cancer Foundation
Netherlands Cancer Institute
Walker Cancer Research Institute
University of California, San Francisco
Broad Institute of MIT and Harvard
National Cancer Centre Singapore
International Agency for Research on Cancer
Associated with oncology and cancer research:
Johnson & Johnson
Merck & Co., Inc.